NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

Why Intellia Therapeutics (NTLA) Is Down 12.6% After FDA Lifts Hold On Key CRISPR Trial

In late January 2026, Intellia Therapeutics announced that the FDA removed the clinical hold on its MAGNITUDE-2 Phase 3 trial of CRISPR-based therapy nexiguran ziclumeran for hereditary transthyretin amyloidosis with polyneuropathy, allowing patient enrollment and dosing to resume under enhanced liver safety monitoring and a slightly expanded enrollment target. This decision marks a key regulatory step for Intellia’s in vivo gene-editing program, highlighting both the promise of a one-time...
NYSE:NEM
NYSE:NEMMetals and Mining

How Investors Are Reacting To Newmont (NEM) Surging With Record Gold Prices And Portfolio Streamlining

In late January 2026, Newmont benefited from record-breaking gold and silver prices driven by geopolitical tensions, economic uncertainty, and strong central bank demand, alongside fresh operational updates at the AME Roundup conference in Vancouver. Together with streamlining after the Newcrest acquisition and plans to sell millions of ounces from core mines, these conditions have sharpened Newmont’s role as a key proxy for safe-haven precious metals exposure. We’ll now examine how this mix...
NYSE:SE
NYSE:SEMultiline Retail

Sea Prioritizes Growth Investments As Valuation Signals Potential Upside

Sea Limited (NYSE:SE) recently reported quarterly results that highlighted strong revenue and gross merchandise value performance. Management chose to prioritize growth initiatives in logistics, fulfillment, and membership programs, even though these moves weigh on near term margins. The company signaled an intention to keep funding these initiatives as it refines its business model and competitive position. Sea runs a broad digital ecosystem across e commerce, digital entertainment, and...
NYSE:LLY
NYSE:LLYPharmaceuticals

Eli Lilly Extends Beyond GLP 1 With Gene Editing And Cancer Push

Eli Lilly (NYSE:LLY) agreed to work with Seamless Therapeutics on gene editing therapies for hearing loss. The company entered a research agreement with Repertoire Immune Medicines to pursue tolerizing therapies for autoimmune diseases. The FDA granted Breakthrough Therapy designation to oncology candidate sofetabart mipitecan for platinum resistant ovarian cancer. Eli Lilly, long known for its diabetes and obesity franchises, is pushing further into genetic medicines and oncology as it...